Distribution of the 21-gene recurrence score (RS) assay (Oncotype DX) in carriers of germline mutations associated with breast cancer predisposition syndromes

被引：0
|
作者：
Giridhar, Karthik V. [1 ]
Choong, Grace M. [1 ]
Yadav, Siddartha [1 ]
Polley, Eric C. [1 ]
Leon-Ferre, Roberto A. [1 ]
Liu, Minetta C. [1 ]
Goetz, Matthew P. [1 ]
Couch, Fergus J. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P5-03-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-03-07
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Use of the 21-gene Oncotype DX® Breast Recurrence Score™ (RS) assay in the neoadjuvant treatment setting
    Robidoux, A.
    McCullough, D.
    Lau, A.
    Stoppler, M.
    Chao, C.
    BREAST, 2017, 32 : S80 - S80
  • [2] 21-Gene Oncotype DX® Recurrence-Score benefits and application in elderly breast cancer patients
    Chiru, E. D.
    Kuhar, C. Grasic
    Oseledchyk, A.
    Kurzeder, C.
    Vetter, M.
    SWISS MEDICAL WEEKLY, 2022, 152 : 43S - 43S
  • [3] Evaluation Oncotype DX® 21-Gene Recurrence Score and clinicopathological parameters in early stage breast cancer
    Lashen, A. L.
    Toss, M. T.
    Fadhil, W. F.
    Oni, G. O.
    Madhusudan, S. M.
    Rakha, E. R.
    JOURNAL OF PATHOLOGY, 2023, 261 : S10 - S10
  • [4] Genetic Ancestry and 21-Gene Oncotype DX Breast Cancer Recurrence Scores
    Borowsky, Peter A.
    Hernandez, Alexandra E.
    Kesmodel, Susan B.
    Goel, Neha
    ANNALS OF SURGICAL ONCOLOGY, 2025,
  • [5] Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence between Breast Cancer Index (BCI) and 21-gene Oncotype DX Recurrence Score (RS)
    Patel, Rima
    Casasanta, Nicole
    Li, Zhiqiang
    Kier, Melanie
    Blanter, Julia
    Sohval, Sophie
    Hovstadius, Malin
    Wu, Catherine
    Fink, Marc
    Zhou, Xiang
    Zimmerman, Brittney
    Cascetta, Krystal
    Chen, Rong
    Oh, William
    Tiersten, Amy
    CANCER RESEARCH, 2023, 83 (05)
  • [6] Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS)
    Casasanta, Nicole
    Patel, Rima
    Raymond, Samantha
    Kier, Melanie W.
    Blanter, Julia
    Sohval, Sophie
    Hovstadius, Malin
    Wu, Catherine
    Zimmerman, Brittney
    Cascetta, Krystal
    Bagiella, Emilia
    Tiersten, Amy
    CLINICAL BREAST CANCER, 2024, 24 (07) : 585 - 596
  • [7] The 21-Gene Recurrence Score Assay (Oncotype DX™) in Estrogen Receptor-Positive Male Breast Cancer: Experience in an Israeli Cohort
    Grenader, Tal
    Yerushalmi, Rinat
    Tokar, Margarita
    Fried, Georgeta
    Kaufman, Bella
    Peretz, Tamar
    Geffen, David B.
    ONCOLOGY, 2014, 87 (01) : 1 - 6
  • [8] Clinical utility of the 21-gene Oncotype DX® Recurrence Score® (RS) assay in hormone receptor-positive, HER2-negative breast cancer (BC)
    Lau, A.
    Miller, D.
    Davison, D.
    Rothney, M.
    Borgen, P.
    BREAST, 2017, 32 : S97 - S97
  • [9] Change in 21-gene recurrence score (RS) (Oncotype DX) after exposure to neoadjuvant endocrine therapy.
    Hilal, Talal
    Mi, Lanyu
    Anderson, Karen S.
    Pockaj, Barbara A.
    Gray, Richard J.
    Dixon, Leslie E.
    Martinez, Erika D.
    Singh, Charanjit
    Northfelt, Donald W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Obesity at diagnosis and breast cancer (BC) recurrence risk based on the 21-gene assay recurrence score (RS).
    Ridolfi, Kimberly
    Zhang, Chong
    Onitilo, Adedayo A.
    Ledesma, Wendy M.
    Andreason, Molly
    Engel, Jessica Marie
    Kim, KyungMann
    Wisinski, Kari Braun
    Tevaarwerk, Amye
    Charlson, John A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345